Skip to main content.

Da Zhang, M.D.

Da Zhang portrait
Professor, Pathology and Laboratory Medicine

Professional Background

Da Zhang, Professor
Program Director of Hematopathology Fellowship
Medical Director of Bone Marrow Lab
Pathology and Laboratory Medicine, University of Kansas Medical Center
Office Address: 3901 Rainbow Boulevard Kansas, MS3045, City KS 66160

Education and Training
  • MD, Medicine, Shandong Medical University
  • MSC, Master of Science, Chinese Center for Disease Control and Prevention, Beijing, Beijing
  • Clinical Fellowship, Hematopathology, Memorial Sloan-Kettering Cancer Center, New York City, New York
  • Residency, Pathology, Medical University of South Carolina, Charleston, SC
Licensure, Accreditations & Certifications
  • Anatomic Pathology and Clinical Pathology, The American Board of Pathology
  • Hematopathology, The American Board of Pathology
  • Kansas
Professional Affiliations
  • College of American Pathologists, Fellow, 2007 - Present
  • Renal Pathologist Society, Member, 2007 - Present
  • Society for Hematopathology, Member, 2007 - Present
  • United States and Canadian Academy of Pathology, Fellow, 2007 - Present



I have been actively involved translational research program in KUMC as a principal investor and co- principal investor in hematopoietic neoplasms and GU research. I am especially interested in Castleman's disease, lymphomas and leukemia.

  • Zhang, Da. 2022. Comparison of flow cytometry and next-generation sequencing in minimal residual disease monitoring of acute myeloid leukemia: One institute's practical clinical experience.
  • 2022. TMEM158 expression is negatively regulated by AR signaling and associated with favorite survival outcomes in prostate cancers
  • 2022. Canonical and non-canonical Wnt signal pathway in classic Hodgkin lymphoma and the prognostic significance of LEF1, β-catenin, FZD6 and Wnt5a/b
  • 2022. Morphologic, immunophenotypic, and molecular genetic comparison study in patients with clonal cytopenia of undetermined significance, myelodysplastic syndrome, and acute myeloid leukemia with myelodysplasia-related changes: A single institution experience